| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its Q4 earnings results on Wednesday, February 28, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
Jazz Pharmaceuticals missed estimated earnings by -3.0%, reporting an EPS of $5.02 versus an estimate of $5.16.
Revenue was up $39.88 million from the same period last year.
Last quarter the company missed on EPS by $0.07 which was followed by a 9.0% drop in the share price the next day.
Here's a look at Jazz Pharmaceuticals's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | 4.91 | 4.43 | 4.24 | 0.32 |
| EPS Actual | 4.84 | 4.51 | 3.95 | -0.07 |
| Revenue Estimate | 965.73M | 942.86M | 895.37M | 975.59M |
| Revenue Actual | 972.14M | 957.32M | 892.81M | 972.12M |
To track all earnings releases for Jazz Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: JAZZ
